Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1627-1629

  Song, Ivy ^a   Borland, Julie ^a   Chen, Shuguang ^a   Patel, Parul ^a   Wajima, Toshihiro ^b   Peppercorn, Amanda ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG SAFETY; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

EID: 84863115993     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05739-11     Document Type: Article

References (9)

1. Brainard DM, et al. 2011. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J. Clin. Pharmacol. 51:422-477.
2. Bristol-Myers Squibb. 2011. Atripla (package insert). Bristol-Myers Squibb and Gilead Sciences, New York, NY.
3. Kobayashi M, et al. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813-821.
4. Lenz JC, Rockstroh JK. 2011. S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin. Invest. Drugs 20:537-548.
5. Min S, et al. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 54:254-258.
6. Song I, et al. 2011. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients, abstr. WEPEB250. 5th Conf. HIV Pathog. Treat. Prevent., Cape Town, South Africa. International AIDS Society, Geneva, Switzerland.
7. Soriano V, et al. 2011. Dolutegravir (DTG, S/GSK1349572) treatment of subjects with raltegravir (RAL) resistance: viral suppression at week 24 in the VIKING study, abstr. PS 1/2. 13th Eur. AIDS Conf., 12 to 15 October 2011, Belgrade, Serbia. European AIDS Clinical Society, Paris, France.
8. Tibotec Therapeutics. 2010. Prezista (package insert). Tibotec Therapeutics, Raritan, NJ.
9. van Lunzen J, et al. 20 October 2011. Once daily dolutegravir (S/ GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose ranging, randomized, phase 2b trial. Lancet Infect. Dis. doi:10.1016/S1473-3099(11)70290-0.